Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KURA | US
-0.46
-2.49%
Healthcare
Biotechnology
30/06/2024
04/10/2024
18.04
18.35
18.65
18.03
Kura Oncology Inc. a clinical-stage biopharmaceutical company develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology Inc. was founded in 2014 and is headquartered in San Diego California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
22.3%1 month
34.7%3 months
39.0%6 months
39.7%-
-
3.21
0.04
0.03
-2.48
-
-
-199.22M
1.38B
1.38B
-
-
-
-
-39.27
26.53
14.17
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.37
Range1M
3.37
Range3M
5.74
Rel. volume
0.92
Price X volume
8.16M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Rocket Pharmaceuticals Inc | RCKT | Biotechnology | 16.41 | 1.49B | -3.24% | n/a | 6.71% |
IRON | IRON | Biotechnology | 49.93 | 1.48B | -2.48% | n/a | 0.38% |
Cassava Sciences Inc | SAVA | Biotechnology | 27.08 | 1.45B | 0.52% | n/a | 0.00% |
Dynavax Technologies Corporation | DVAX | Biotechnology | 11.02 | 1.44B | -2.91% | 84.62 | 39.71% |
NRIX | NRIX | Biotechnology | 22.2 | 1.43B | 1.05% | n/a | 7.77% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 36.22 | 1.41B | -0.55% | n/a | 1.31% |
Xencor Inc | XNCR | Biotechnology | 19.85 | 1.39B | 2.00% | n/a | 15.54% |
Day One Biopharmaceuticals Inc. Common Stock | DAWN | Biotechnology | 14.1 | 1.39B | 3.52% | n/a | 0.06% |
SPRY | SPRY | Biotechnology | 14.19 | 1.38B | -1.80% | n/a | 0.07% |
Tarsus Pharmaceuticals Inc | TARS | Biotechnology | 33.89 | 1.31B | 3.48% | n/a | 28.62% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.48 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 3.21 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 38.97 | 74.67 | Lower Risk |
Debt to Equity | 0.04 | -1.82 | Expensive |
Debt to Assets | 0.03 | 0.26 | Cheaper |
Market Cap | 1.38B | 3.73B | Emerging |